Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering.

Area of Science:

• Biochemistry
• Structural Biology
• Drug Discovery

Background:

• Mitogen-activated protein (MAP) kinase p38 alpha is a key mediator of inflammatory responses.
• It is an important therapeutic target for inflammatory and autoimmune diseases.
• Previous crystallization efforts for p38 alpha yielded small, mosaic crystals, hindering high-resolution studies.

Purpose of the Study:

• To improve the quality and stability of mitogen-activated protein kinase p38 alpha for structure-based drug design.
• To overcome crystallization challenges associated with the wild-type enzyme.

Main Methods:

• Site-directed mutagenesis was used to introduce a single point mutation (C162S) in a surface cysteine residue.
• Crystallographic and biochemical analyses were performed on the mutant protein.
• The impact of the mutation on enzyme stability, homogeneity, and crystal quality was assessed.

Main Results:

• The C162S mutation prevented protein aggregation and enhanced homogeneity and stability.
• Crystallization of the mutant p38 alpha protein was facilitated, yielding higher quality crystals.
• The mutation induced conformational changes leading to stronger lattice interactions and improved crystal diffraction.

Conclusions:

• The C162S mutation significantly improves the suitability of p38 alpha as a reagent for structure-based drug design.
• This engineered protein facilitates high-resolution structural studies essential for developing novel therapeutics for inflammatory conditions.